Golden Helix Blog

Copy Number Variants Using AMP Guidelines

Oct 10, 2019

The common approaches to detecting copy number variants (CNVs) are chromosomal microarray and MLPA. However, both options increase analysis time, per sample costs, and are limited to the size of CNV events that can be detected. VarSeq’s CNV caller, on the other hand, allows users to detect CNVs from the…

Read more →

Somatic Variant Calling with Sentieon

Oct 7, 2019

Sentieon has become well known for the dramatic improvements it supplies in speed and accuracy for secondary analysis. Luckily, these improvements are not only available for DNAseq germline based variants but also for TNSeq somatic investigation. Sentieon has proven the capability by leading in awards such as the ICGC-TCGA DREAM…

Read more →

Oncogenicity Scoring in VSClinical

Oct 1, 2019

Before examining the clinical evidence associated with a specific mutation, a clinician must establish that the variant is likely to be a driver mutation which generates functional changes that enhance tumor cell proliferation. Our recent blog series “Following the AMP Guidelines with VSClinical” briefly mentioned how the oncogenicity scoring system…

Read more →

Customer Publications Throughout September 2019

Sep 29, 2019

From diagnosing, treating and preventing diseases in humans and animals, to preserving our global food supply, Golden Helix products are being used all over the world! In September, we were cited in many publications spanning a diverse range of species and topics. Below are brief recaps of a few of…

Read more →

Getting the most out of Sentieon

Sep 26, 2019

Customers are always asking for ways to improve their experience with Sentieon, our partner’s secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, exceptional accuracy and 100% consistency. We have a few tips to get the most out of Sentieon. In this article I will…

Read more →

Variant Interpretation with VSClinical: RET-KIF5b Gene Fusion

Sep 24, 2019

Gene Fusion Background Gene fusions are hybrid genes that result from translocations, interstitial deletions, or chromosomal inversions that can lead to constitutive gene activation and result in increased or abnormal protein production. Increased or abnormal protein production subsequently can play an important role in tumorigenesis and thus identifying and evaluating…

Read more →

Updated Annotations: The New and Improved gnomAD 2.1.1

Sep 19, 2019

The Broad Institute team led by Dan MacArthur announced the release of gnomAD version 2.1 at last year’s ASHG conference. This new version boasted data from 125,748 exomes and 15,708 genomes, but the greater updates were the improved QC refinement and more discrete sub-population break downs. Although the majority of…

Read more →

Automating & Standardizing Your NGS Workflow: Part IV

Sep 10, 2019

We have covered a lot of ground in this Automating & Standardizing Your Workflows blog series. First, we saw how to perform secondary analysis with Sentieon to generate the necessary VCF and BAM files for tertiary analysis in Part I. The implementation of VSPipeline allowed for rapid import and project…

Read more →

Following the AMP Guidelines with VSClinical: Part II

Sep 5, 2019

VSClinical  users can interpret and report genomic mutations in cancer following the AMP guidelines which we’re demonstrating in this “Following the AMP Guidelines with VSClinical” blog series. Part I introduced the hands-on analysis steps involved in creating a high-quality clinical report for targeted Next-Generation Sequencing (NGS) assays. We reviewed sample and variant quality, including the depth of coverage over the target…

Read more →

Automating & Standardizing Your NGS Workflow: Part III

Sep 3, 2019

In our last part of this series, we showed how to run a pre-built workflow template via VSPipeline to automatically import and filter sample variants to streamline the search for clinically relevant variants. Now, we can deep-dive into our filtered, pathogenic variants to fully understand and capture their final classification…

Read more →

Automating & Standardizing Your NGS Workflow: Part II

Aug 29, 2019

VSPipeline: Automating your Tertiary Workflows The first part of this “Automating & Standardizing your NGS Workflow” blog series covered the secondary analysis steps of read alignment and variant calling with Sentieon. The next step is to transition into the tertiary analysis via utilization of our workflow automation tool, VSPipeline. VSPipeline…

Read more →

Customer Publications Throughout Summer 2019

Aug 26, 2019

We are always excited to see how our software is used to support research and enable precision medicine. We believe that our customer’s success is ultimately our success! This summer was filled with many wonderful publications from across the globe and we are proud to have been a part of…

Read more →

Following the AMP Guidelines with VSClinical: Part I

Aug 23, 2019

In the world of genomics shaping precision medicine in oncology, the limiting factor is the time-to-sign-out of a fully interpreted molecular profile report. There are many components of the entire testing process that add to the turn-around time of each test. Many of these steps, such as sample prep, sequencing, and automated secondary analysis,…

Read more →

Variant Interpretation with VSClinical: Non-Small Cell Lung Cancer

Aug 20, 2019

With the increasing knowledge of mutations involved in cancer, it is imperative to have a tertiary analysis pipeline that provides users with the most up to date information on somatic mutations. VSClinical’s Cancer Add-On does just that and more; with this feature, users can investigate and report on SNVs, indels,…

Read more →

Golden Helix Named to the 2019 Inc. 5000 List of Fastest-Growing Private Companies

Aug 16, 2019

Earlier this week, Inc. magazine ranked Golden Helix on the 2019 Inc. 5000 list with three-year revenue growth of 61%. The Inc. 5000 list represents a unique look at the most successful companies within the American economy’s most dynamic segment—its independent small businesses. Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn,…

Read more →

2019 T-Shirt Design Competition Winners

Aug 15, 2019

We would like to thank everyone who participated in our 2019 t-shirt design competition. It was great to see the amount of creativity our community expressed! We are pleased to announce this year’s winners: First Place – Dr. Marina Trigueros Dr. Marina Trigueros is a Science Illustrator and 3D Animator…

Read more →

Variant Interpretation with VSClinical: Huntington’s Disease (HD)

Aug 12, 2019

Huntington’s Disease (HD) Background Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disease that is caused by a mutation in the huntingtin (HTT) gene resulting in 36 or more CAG trinucleotide repeats in exon 1. Individuals affected by HD experience motor disorders including involuntary movements and poor coordination, cognitive impairments…

Read more →

Automating & Standardizing Your NGS Workflow: Part I

Aug 5, 2019

Secondary Analysis with Sentieon: Rapid and Accurate Variant Calling This blog post will cover the utilization of secondary analysis tools to produce a list of high-quality variants and associated coverage data. This data will serve as the main, importable content for the tertiary stage of analysis where variants are interpreted…

Read more →

Automating & Standardizing Your NGS Workflow

Jul 30, 2019

As our regular customers may know, we write our blogs to provide relevant content to any NGS-based analysis with VarSeq. Our goal here at Golden Helix is to provide top quality software and guidance on how to use the software efficiently to perform variant analysis. However, this blog series will…

Read more →

Variant Interpretation with VSClinical: Congenital Myasthenic Syndromes (CMS)

Jul 26, 2019

Congenital Myasthenic Syndromes (CMS) History: Congenital Myasthenic Syndromes (CMS) are a group of rare hereditary conditions that can cause seizures, severe muscle weakness, respiratory problems, and potentially disabling weaknesses shortly after birth or early childhood (1). CMS is the result of abnormalities in acetylcholine proteins residing in the motor endplate…

Read more →